STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways ...

A 5-year-old boy from Center City has faced rare odds since birth and now this warrior is in a real life race to rewrite his story.

UniQure said it has aligned with the FDA on components of a statistical analysis plan for a registrational trial of AMT-130.

In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Mice lived 30% longer with a cancer drug combo that also slowed aging, reduced disease, and rewired gene activity.

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

Preliminary data from ongoing Phase 1/2 trials show BEAM-302 is well tolerated and achieves dose-dependent, durable ...

Cardiovascular disease and kidney disease are two of the most urgent issues in global public health. In the United States ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has announced pivotal progress in its TSHA-102 gene therapy program for Rett ...

FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...